Belmontesi Magda
Studio Belmontesi, Vigevano, Italy.
J Cosmet Dermatol. 2020 Nov;19(11):2982-2986. doi: 10.1111/jocd.13710. Epub 2020 Sep 21.
Post-surgery disabling scars are frequent after surgical interventions.
We evaluated a new strategy for scars management.
A woman with a postsurgery disabling scar, consequent to an accident that needed surgical intervention, had serious difficulties to walk and perform normal daily activities. A few months after the intervention, she was treated with a combined therapy consisting of polydeoxyribonucleotide (PDRN) vials 5.625 mg/3 mL (administered subcutaneously as a biostimulant treatment through the scars and throughout the whole atrophic area), associated with nucleotide administered topically and as a food supplement. The patient was treated with an additional topical nighttime treatment cream based on nucleotides, hyaluronic acid, Allium cepa extract, and vitamin E, plus a daily treatment with a cream containing nucleotides, and a nutraceutical systemic treatment with 25 mg/cps of nucleotides and 5 mg/cps of Q10-coenzyme (1 cps/d).
This reasonably cheap treatment was effective and safe for this disabling scar at the right foot. One year after starting treatment, the patient confirmed her complete satisfaction. This is the first case report describing an unexpectedly successful outcome while using this combination therapy on a woman with a postsurgery disabling scar.
手术后致残性瘢痕在外科手术后很常见。
我们评估了一种新的瘢痕管理策略。
一名女性因意外事故接受手术干预后留下了致残性瘢痕，行走和进行正常日常活动都存在严重困难。干预几个月后，她接受了联合治疗，包括5.625毫克/3毫升的聚脱氧核糖核苷酸（PDRN）小瓶（作为生物刺激剂皮下注射到瘢痕及整个萎缩区域），同时局部使用核苷酸并作为食品补充剂。患者还接受了额外的夜间局部治疗乳膏，其成分包括核苷酸、透明质酸、洋葱提取物和维生素E，另外每天使用含核苷酸的乳膏进行治疗，并进行营养补充剂全身治疗，即每天服用25毫克/胶囊的核苷酸和5毫克/胶囊的辅酶Q10（1胶囊/天）。
这种价格合理的治疗方法对右脚的致残性瘢痕有效且安全。开始治疗一年后，患者表示完全满意。这是第一例报告，描述了在一名手术后致残性瘢痕女性患者中使用这种联合治疗取得意外成功的结果。
